<?xml version='1.0' encoding='utf-8'?>
<document id="28795412"><sentence text="Severe neurological disorders and refractory aspergillosis in an adolescent treated by vincristine and voriconazole."><entity charOffset="87-98" id="DDI-PubMed.28795412.s1.e0" text="vincristine" /><entity charOffset="103-115" id="DDI-PubMed.28795412.s1.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.28795412.s1.e0" e2="DDI-PubMed.28795412.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28795412.s1.e0" e2="DDI-PubMed.28795412.s1.e1" /></sentence><sentence text="Voriconazole and vincristine are major therapeutics in paediatric haematology"><entity charOffset="0-12" id="DDI-PubMed.28795412.s2.e0" text="Voriconazole" /><entity charOffset="17-28" id="DDI-PubMed.28795412.s2.e1" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.28795412.s2.e0" e2="DDI-PubMed.28795412.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28795412.s2.e0" e2="DDI-PubMed.28795412.s2.e1" /></sentence><sentence text=" However, the risk-benefit ratio of the treatment of invasive aspergillosis with voriconazole in patients receiving vincristine-based chemotherapy remains unclear"><entity charOffset="81-93" id="DDI-PubMed.28795412.s3.e0" text="voriconazole" /><entity charOffset="116-127" id="DDI-PubMed.28795412.s3.e1" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.28795412.s3.e0" e2="DDI-PubMed.28795412.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28795412.s3.e0" e2="DDI-PubMed.28795412.s3.e1" /></sentence><sentence text="" /><sentence text="We report severe peripheral and central neurological disorders in a 14-year-old girl with T-cell acute lymphoblastic leukaemia and pulmonary aspergillosis" /><sentence text=" The case describes a strong exacerbation by voriconazole of the vincristine-induced neuropathic pains"><entity charOffset="45-57" id="DDI-PubMed.28795412.s6.e0" text="voriconazole" /><entity charOffset="65-76" id="DDI-PubMed.28795412.s6.e1" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.28795412.s6.e0" e2="DDI-PubMed.28795412.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28795412.s6.e0" e2="DDI-PubMed.28795412.s6.e1" /></sentence><sentence text=" It shows the high variability of the trough serum concentration of voriconazole leading to antifungal treatment failure and suggests that its own central neurotoxicity could also be potentiated by vincristine"><entity charOffset="68-80" id="DDI-PubMed.28795412.s7.e0" text="voriconazole" /><entity charOffset="198-209" id="DDI-PubMed.28795412.s7.e1" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.28795412.s7.e0" e2="DDI-PubMed.28795412.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28795412.s7.e0" e2="DDI-PubMed.28795412.s7.e1" /></sentence><sentence text="" /><sentence text="Given the risk of either insufficient antifungal efficacy or excessive neurological disorders, this case warns on a probable unfavourable risk-benefit profile of voriconazole during vincristine-based chemotherapy in adolescents"><entity charOffset="162-174" id="DDI-PubMed.28795412.s9.e0" text="voriconazole" /><entity charOffset="182-193" id="DDI-PubMed.28795412.s9.e1" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.28795412.s9.e0" e2="DDI-PubMed.28795412.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28795412.s9.e0" e2="DDI-PubMed.28795412.s9.e1" /></sentence><sentence text="" /></document>